LSL Pharma Group (TSXV:LSL) Moat Score: 0/10 (As of Jun. 30, 2026)


TSXV:LSL LSL Pharma Group Inc TSXV:LSL
50 GF Score
Price C$0.32
GF Value C$0.72
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is LSL Pharma Group Moat Score?

LSL Pharma Group has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

LSL Pharma Group has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes LSL Pharma Group might have No Moat - No discernible moat.

LSL Pharma Group  (TSXV:LSL) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

LSL Pharma Group Moat Score Related Terms

TSXV:LSL
50GF Score
LSL Pharma Group Inc TSXV:LSL
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?

Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued. The current stock price of C$0.32 is trading 56.3% below its estimated GF Value™ of C$0.72. GuruFocus considers LSL Pharma Group to be Possible Value Trap.

Key valuation signals for TSXV:LSL:

  • Moat Score: 0
  • GF Value™: C$0.72 vs. price of C$0.32 (56.3% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LSL Pharma Group Business Description

Address 540, rue d\'Avaugour, Bureau 1800, Boucherville, QC, CAN, J4B 0G6
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
50GF Score

Get the complete analysis for TSXV:LSL

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.32
Price
C$0.72
GF Value